Posttransplantation lymphoproliferative disease: Proposed imaging classification

Juan C. Camacho, Courtney Coursey Moreno, Peter A. Harri, Diego A. Aguirre, William E. Torres, Pardeep Kumar Mittal

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Posttransplantation lymphoproliferative disease (PTLD) is the second most common tumor in adult transplant recipients. Most cases of PTLD are attributed to Epstein-Barr virus. Decreased levels of immunosurveillance against this tumor virus as a result of immunosuppressive regimens are thought to account for most cases of PTLD. Histologically, PTLD ranges from relatively benign lymphoid hyperplasia to poorly differentiated lymphoma, and tissue sampling is required to establish the subtype. The frequency of PTLD varies depending on the type of allograft and immunosuppressive regimen. PTLD has a bimodal manifestation, with most cases occurring within the first year after transplantation and a second peak occurring 4–5 years after transplantation. Patients are often asymptomatic or present with nonspecific symptoms, and a mass visible at imaging may be the first clue to the diagnosis. Imaging plays an important role in identifying the presence of disease, guiding tissue sampling, and evaluating response to treatment. The appearance of PTLD at imaging can vary. It may be nodal or extranodal. Extranodal disease may involve the gastrointestinal tract, solid organs, or central nervous system. Solid organ lesions may be solitary or multiple, infiltrate beyond the organ margins, and obstruct organ outflow. Suggestive imaging findings should prompt tissue sampling, because knowledge of the PTLD subtype is imperative for appropriate treatment. Treatment options include reducing immunosuppression, chemotherapy, radiation therapy, and surgical resection of isolated lesions.

Original languageEnglish (US)
Pages (from-to)2025-2038
Number of pages14
JournalRadiographics
Volume34
Issue number7
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Immunosuppressive Agents
Transplantation
Immunologic Monitoring
Oncogenic Viruses
Human Herpesvirus 4
Immunosuppression
Hyperplasia
Allografts
Gastrointestinal Tract
Lymphoma
Radiotherapy
Therapeutics
Central Nervous System
Drug Therapy
Neoplasms
Transplant Recipients

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Camacho, J. C., Moreno, C. C., Harri, P. A., Aguirre, D. A., Torres, W. E., & Mittal, P. K. (2014). Posttransplantation lymphoproliferative disease: Proposed imaging classification. Radiographics, 34(7), 2025-2038. https://doi.org/10.1148/rg.347130130

Posttransplantation lymphoproliferative disease : Proposed imaging classification. / Camacho, Juan C.; Moreno, Courtney Coursey; Harri, Peter A.; Aguirre, Diego A.; Torres, William E.; Mittal, Pardeep Kumar.

In: Radiographics, Vol. 34, No. 7, 01.01.2014, p. 2025-2038.

Research output: Contribution to journalArticle

Camacho, JC, Moreno, CC, Harri, PA, Aguirre, DA, Torres, WE & Mittal, PK 2014, 'Posttransplantation lymphoproliferative disease: Proposed imaging classification', Radiographics, vol. 34, no. 7, pp. 2025-2038. https://doi.org/10.1148/rg.347130130
Camacho, Juan C. ; Moreno, Courtney Coursey ; Harri, Peter A. ; Aguirre, Diego A. ; Torres, William E. ; Mittal, Pardeep Kumar. / Posttransplantation lymphoproliferative disease : Proposed imaging classification. In: Radiographics. 2014 ; Vol. 34, No. 7. pp. 2025-2038.
@article{e98ae54c82d446d2b30730103f895457,
title = "Posttransplantation lymphoproliferative disease: Proposed imaging classification",
abstract = "Posttransplantation lymphoproliferative disease (PTLD) is the second most common tumor in adult transplant recipients. Most cases of PTLD are attributed to Epstein-Barr virus. Decreased levels of immunosurveillance against this tumor virus as a result of immunosuppressive regimens are thought to account for most cases of PTLD. Histologically, PTLD ranges from relatively benign lymphoid hyperplasia to poorly differentiated lymphoma, and tissue sampling is required to establish the subtype. The frequency of PTLD varies depending on the type of allograft and immunosuppressive regimen. PTLD has a bimodal manifestation, with most cases occurring within the first year after transplantation and a second peak occurring 4–5 years after transplantation. Patients are often asymptomatic or present with nonspecific symptoms, and a mass visible at imaging may be the first clue to the diagnosis. Imaging plays an important role in identifying the presence of disease, guiding tissue sampling, and evaluating response to treatment. The appearance of PTLD at imaging can vary. It may be nodal or extranodal. Extranodal disease may involve the gastrointestinal tract, solid organs, or central nervous system. Solid organ lesions may be solitary or multiple, infiltrate beyond the organ margins, and obstruct organ outflow. Suggestive imaging findings should prompt tissue sampling, because knowledge of the PTLD subtype is imperative for appropriate treatment. Treatment options include reducing immunosuppression, chemotherapy, radiation therapy, and surgical resection of isolated lesions.",
author = "Camacho, {Juan C.} and Moreno, {Courtney Coursey} and Harri, {Peter A.} and Aguirre, {Diego A.} and Torres, {William E.} and Mittal, {Pardeep Kumar}",
year = "2014",
month = "1",
day = "1",
doi = "10.1148/rg.347130130",
language = "English (US)",
volume = "34",
pages = "2025--2038",
journal = "Radiographics",
issn = "0271-5333",
publisher = "Radiological Society of North America Inc.",
number = "7",

}

TY - JOUR

T1 - Posttransplantation lymphoproliferative disease

T2 - Proposed imaging classification

AU - Camacho, Juan C.

AU - Moreno, Courtney Coursey

AU - Harri, Peter A.

AU - Aguirre, Diego A.

AU - Torres, William E.

AU - Mittal, Pardeep Kumar

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Posttransplantation lymphoproliferative disease (PTLD) is the second most common tumor in adult transplant recipients. Most cases of PTLD are attributed to Epstein-Barr virus. Decreased levels of immunosurveillance against this tumor virus as a result of immunosuppressive regimens are thought to account for most cases of PTLD. Histologically, PTLD ranges from relatively benign lymphoid hyperplasia to poorly differentiated lymphoma, and tissue sampling is required to establish the subtype. The frequency of PTLD varies depending on the type of allograft and immunosuppressive regimen. PTLD has a bimodal manifestation, with most cases occurring within the first year after transplantation and a second peak occurring 4–5 years after transplantation. Patients are often asymptomatic or present with nonspecific symptoms, and a mass visible at imaging may be the first clue to the diagnosis. Imaging plays an important role in identifying the presence of disease, guiding tissue sampling, and evaluating response to treatment. The appearance of PTLD at imaging can vary. It may be nodal or extranodal. Extranodal disease may involve the gastrointestinal tract, solid organs, or central nervous system. Solid organ lesions may be solitary or multiple, infiltrate beyond the organ margins, and obstruct organ outflow. Suggestive imaging findings should prompt tissue sampling, because knowledge of the PTLD subtype is imperative for appropriate treatment. Treatment options include reducing immunosuppression, chemotherapy, radiation therapy, and surgical resection of isolated lesions.

AB - Posttransplantation lymphoproliferative disease (PTLD) is the second most common tumor in adult transplant recipients. Most cases of PTLD are attributed to Epstein-Barr virus. Decreased levels of immunosurveillance against this tumor virus as a result of immunosuppressive regimens are thought to account for most cases of PTLD. Histologically, PTLD ranges from relatively benign lymphoid hyperplasia to poorly differentiated lymphoma, and tissue sampling is required to establish the subtype. The frequency of PTLD varies depending on the type of allograft and immunosuppressive regimen. PTLD has a bimodal manifestation, with most cases occurring within the first year after transplantation and a second peak occurring 4–5 years after transplantation. Patients are often asymptomatic or present with nonspecific symptoms, and a mass visible at imaging may be the first clue to the diagnosis. Imaging plays an important role in identifying the presence of disease, guiding tissue sampling, and evaluating response to treatment. The appearance of PTLD at imaging can vary. It may be nodal or extranodal. Extranodal disease may involve the gastrointestinal tract, solid organs, or central nervous system. Solid organ lesions may be solitary or multiple, infiltrate beyond the organ margins, and obstruct organ outflow. Suggestive imaging findings should prompt tissue sampling, because knowledge of the PTLD subtype is imperative for appropriate treatment. Treatment options include reducing immunosuppression, chemotherapy, radiation therapy, and surgical resection of isolated lesions.

UR - http://www.scopus.com/inward/record.url?scp=84910068348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910068348&partnerID=8YFLogxK

U2 - 10.1148/rg.347130130

DO - 10.1148/rg.347130130

M3 - Article

C2 - 25384299

AN - SCOPUS:84910068348

VL - 34

SP - 2025

EP - 2038

JO - Radiographics

JF - Radiographics

SN - 0271-5333

IS - 7

ER -